VANCOUVER, BC, June 24,
2024 /PRNewswire/ - The first patient has entered the
Phase II/III trial of ST-02, Sustained Therapeutic's innovative
cancer medication targeting Upper Tract Urethral Carcinoma
(UTUC).
A rare form of cancer, UTUC affects over 7,000 individuals
annually across North America.
UTUC is a cancer of the inside lining of the kidney (the
"collecting system" – where urine starts to drain after it is made
by the kidney) and the ureter (the tube that carries urine from the
kidney to the bladder). Its location in the upper collecting system
makes it challenging to access and completely remove with
traditional laser resection.
"This is a major step forward in the treatment of UTUC," says
Dr. Peter Black, lead investigator
of the clinical trial and a Senior Research Scientist with the
Vancouver Prostate Centre. "Currently we have limited treatment
options for this uncommon and challenging cancer, and this approach
may allow better disease control without having to remove a
kidney."
The first patient in the clinical trial has been enrolled at the
Vancouver Prostate Centre, and it is anticipated that 5 other sites
will take part in the study. The company plans on enrolling
approximately 75 patients in the combined Phase II/III trial and
believes that ST-02 may be designated an orphan drug. Orphan drug
designation can qualify the company for incentives such as tax
credits, exemption from user fees, and seven years of market
exclusivity after approval.
Sustained Therapeutics' ST-02 product for UTUC is a sustained
release formulation that enables direct delivery of chemotherapy to
the site of the carcinoma via a catheter. Using the company's
proprietary platform technology, the medication releases slowly
over about 24 hours exactly where the cancer is located, coating
the tissue and delivering chemotherapy at higher concentrations and
for longer than the current standard of care. The company believes
that this direct sustained delivery may be more effective and
result in fewer side effects than other forms of chemotherapy that
are a current standard of care.
"ST-02 is Sustained Therapeutic's second product to reach Phase
II trials, and demonstrates our potential to develop multiple
products using our novel drug delivery platforms. As such, it is a
very important development in our portfolio," says Dr. Martin Gleave, Founder and Chief Medical Office
of Sustained Therapeutics and Distinguished Professor in the UBC
Department of Urologic Sciences and Director of the Vancouver
Prostate Centre (VPC). "This new therapeutic, designed specifically
for UTUC, could address and important unmet need for patients. It's
an exciting time to be a part of this work."
About Sustained Therapeutics:
Sustained Therapeutics is a clinical-stage company utilizing its
advanced clinical and research expertise to develop its novel
sustained-release drug delivery platform. Its first
product, ST-01, is a non-opioid locally injected sustained-release
therapeutics primarily for the treatment of pain and currently is
in two Phase II trials. A spin-off from the University of British Columbia and the Vancouver
Prostate Centre, has the potential to enable
sustained release treatments for multiple other products, including
in cancer and inflammatory diseases. sustainedtherapeutics.com
Notice Regarding Forward-Looking Statements:
This news release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and forward-looking information within the meaning of
applicable Canadian securities laws (collectively, "forward-looking
statements"), including statements regarding the results of the
Phase I trial, the objectives and potential results of the Phase II
trial, and the potential benefits of the Company's therapeutics.
Statements in this document regarding future expectations, beliefs,
or plans constitute forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ
materially from the statements made. Without limiting the
foregoing, the words "seeks", "believes", "plans", and "indicates"
are intended to identify forward-looking statements. You are
cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause actual results, future
circumstances, or events to differ materially from those projected
in the forward-looking statements. These risks include, but are not
limited to: those associated with the success of research and
development programs, the ability to raise additional funding, and
the need to obtain regulatory approval. Forward-looking statements
are developed based on assumptions about such risks, uncertainties
and other factors, including, but not limited to: research and
development plans proceeding substantially as envisioned, safety of
product, and availability of financing on reasonable terms.
Forward-looking statements are made as of the date hereof, and the
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View original
content:https://www.prnewswire.com/news-releases/sustained-therapeutics-announces-first-patient-for-cancer-trial-302180130.html
SOURCE Sustained Therapeutics